Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.59 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249099 | 1.00 | ITGAV (0.59) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5248276 | 1.00 | ITGAV (0.59) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5249570 | 0.89 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5247605 | 0.89 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5246327 | 0.87 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5249709 | 0.87 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7441104 | 0.86 | ITGAV (0.62) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7434450 | 0.86 | ITGAV (0.62) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7434458 | 0.86 | ITGAV (0.62) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL5245852 | 0.86 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315501-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7056909-B2 | Alpha v integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1315501-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-26 | — | — | US | disclosed |
| EP-1315501-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002007730-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038963-A1 | Alpha v integrin receptor antagonists | ITGAV, ADGRE5, ITGB3 | ITGAV 1/4885ITGB3 3/4885ITGB6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.